NCT01630941View on ClinicalTrials.gov

Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 7, 2012

Primary Completion Date

January 16, 2017

Study Completion Date

March 30, 2017

Conditions
Osteoarthritis, HipAmbulation Difficulty
Interventions
DRUG

denosumab

Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval

Trial Locations (1)

Unknown

Department of Orthopedics, Uppsala

All Listed Sponsors
lead

Hans Mallmin

OTHER

NCT01630941 - Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty | Biotech Hunter | Biotech Hunter